在备受瞩目的精神分裂症认知功能研究宣告未能达到主要临床终点后,生物制药公司Alto Neuroscience Inc(ANRO)股价在延长交易时段遭遇重挫,大幅下跌18.8%,最终报收于19.01美元。这一关键临床试验结果的失利,无疑给投资者对该公司核心管线前景的预期带来了显著冲击。
在备受瞩目的精神分裂症认知功能研究宣告未能达到主要临床终点后,生物制药公司Alto Neuroscience Inc(ANRO)股价在延长交易时段遭遇重挫,大幅下跌18.8%,最终报收于19.01美元。这一关键临床试验结果的失利,无疑给投资者对该公司核心管线前景的预期带来了显著冲击。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.